This pilot study aimed to determine early changes of LXA(4) levels among the hospitalized
patients confirmed as COVID-19 cases following the clinical management and its correlation
with commonly used inflammatory markers, including erythrocyte sedimentation rate
(ESR), c-reactive protein (CRP), and ferritin. Thirty-one adult hospitalized patients
infected with the nonsevere COVID-19 were included. LXA(4) levels were measured at
the baseline and 48-72 hours after hospitalization. Accordingly, ESR and CRP levels
were collected on the first day of hospitalization. Moreover, the maximum serum ferritin
levels were determined during the five days. LXA(4) levels significantly increased
at 48-72 hours compared to the baseline. ESR, CRP, and ferritin levels were positively
correlated with the increased LXA(4). In contrast, aging was shown to negatively correlate
with the increased LXA(4) levels. LXA(4) may be known as a valuable marker to assess
the treatment response among non-elderly patients with non-severe COVID-19. Furthermore,
LXA(4) could be considered as a potential treatment option under inflammatory conditions.
Further studies are necessary to clarify LXA(4) role in COVID-19 pathogenesis, as
well as the balance between such pro-resolving mediators and inflammatory parameters.
